Unknown

Dataset Information

0

Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.


ABSTRACT: Recent studies have revealed significant efficacy of the marine sponge glycolipid, alpha-galactosylceramide (alpha-GalCer), in treatment of experimental metastatic cancers, infections, and autoimmune diseases. However, the capacity of alpha-GalCer to prevent tumor development had never, to our knowledge, been evaluated in mouse models of chemical- and oncogene-dependent carcinogenesis. In this study, we demonstrate that long-term administration of soluble alpha-GalCer, spanning the time of tumor initiation, inhibits primary tumor formation in three different models: methylcholanthrene-induced sarcomas, mammary carcinomas in Her-2/neu transgenic mice, and spontaneous sarcomas in p53-/- mice. Weekly treatment of mice with alpha-GalCer maintained lymphoid tissue natural killer cell and T cell activation and elevated serum IFN-gamma and IL-4 concentrations. Consistent with the antimetastatic activity of alpha-GalCer, prevention of methylcholanthrene-induced sarcoma was IFN-gammaand tumor necrosis factor-related apoptosis-inducing ligand dependent, but not perforin-dependent. Taken together, our results demonstrate that NK1.1+alphabetaTCR+ cell-based immune therapy can inhibit primary tumorigenesis.

SUBMITTER: Hayakawa Y 

PROVIDER: S-EPMC170941 | biostudies-other | 2003 Aug

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC4355080 | biostudies-literature
| S-EPMC3813944 | biostudies-literature
| S-EPMC4966329 | biostudies-literature
| S-EPMC3908749 | biostudies-literature
| S-EPMC2675057 | biostudies-literature
| S-EPMC4799762 | biostudies-literature
| S-EPMC3065778 | biostudies-literature
| S-EPMC1270467 | biostudies-other
| S-EPMC3786381 | biostudies-literature
2013-06-30 | E-GEOD-41422 | biostudies-arrayexpress